Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction

Title:Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction

Volume: 24 Issue: 14

Author(s): María Miguélez González*, Alba Galdón Sanz-Pastor, Roberto Áñez Gómez, Noemi Brox Torrecilla, Diego Muñoz Moreno, Laura González Fernández, Alejandra Maricel Rivas, Aurelio López Guerra, Rosa Álvarez, José Ángel Arranz, Iván Márquez Rodas, Vicente Escudero, María Sanjurjo, Javier Martín Vallejo, Miguel Martín and Olga González Albarrán

Affiliation:

• Department of Endocrinology, Hospital General Universitario Gregorio, Marañón, Madrid, Spain

Abstract: Objective: The purpose of this study was to identify predictive and risk factors for the development of immune-related endocrinopathies and to analyze the incidence and characteristics of immune-related endocrinopathies in our population

Design: A retrospective, single-centre cohort carried out at Gregorio Marañón Hospital between January 2018 -December 2019.

Methods: A total of 163 patients were enrolled. In January 2018 and December 2019, we treated patients who underwent ICI treatment in the Medical Oncology Department of General University Hospital Gregorio Marañón, a tertiary care public hospital in Madrid, as part of an observational, retrospective, single-center cohort study.

Results: Endocrinopathies were diagnosed in 19.5% of the patients (n = 32). The tumours with the highest incidence of endocrinopathies were non-small cell lung cancer (25,9%), kidney cell cancer (25%) and hepatocarcinoma (20%). Among the 32 patients who developed endocrinopathy, 18,8%, 19,13%, and 21,28% received anti-CTLA-4, anti-PD-1 and anti-PDL-1, respectively. Thyroid dysfunction was the most frequent endocrinopathy (12,8%). A higher percentage of patients with negative antiTPO and antiTG antibodies developed G1 hypothyroidism compared to patients with positive antibodies who developed a higher proportion of G2 hypothyroidism. The presence of an initial phase of thyrotoxicity was not related to greater severity. We observed longer progression-free survival in patients who developed thyroid dysfunction.

Conclusion: Pre-existing antibodies were independently associated with endocrinopathies. Moreover, our study let us conclude that the presence of thyroid autoantibodies may be related to its severity. It is important to determine anti-thyroid antibodies prior to the start of immunotherapy as a risk factor for thyroid dysfunction, which in turn is a prognostic marker.

Cite this article as:

Miguélez González María*, Galdón Sanz-Pastor Alba, Áñez Gómez Roberto, Brox Torrecilla Noemi, Muñoz Moreno Diego, González Fernández Laura, Maricel Rivas Alejandra, López Guerra Aurelio, Álvarez Rosa, Arranz José Ángel, Márquez Rodas Iván, Escudero Vicente, Sanjurjo María, Martín Vallejo Javier, Martín Miguel and González Albarrán Olga, Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction, Endocrine, Metabolic & Immune Disorders - Drug Targets 2024; 24 (14) . https://dx.doi.org/10.2174/0118715303280679240206100137